EGFR-mutation testing and TKI treatment patterns in locally advanced or metastatic NSCLC in Norway: A nationwide cohort study

被引：0
|
作者：
Helland, A. [1 ]
Andersen, K. K. [2 ]
Myklebust, T. A. [3 ]
Johannesen, T. B. [3 ]
Hallerback, T. [4 ]
Enerly, E. [5 ]
机构：
[1] Oslo Univ Hosp, Dept Oncol, Oslo, Norway
[2] AstraZeneca Nord Balt, Med Evidence Denmark, Ballerup, Denmark
[3] Canc Registry Norway, Dept Registrat, Oslo, Norway
[4] AstraZeneca Nord Balt, Med Evidence Sweden, Sodertaelje, Sweden
[5] Canc Registry Norway, Dept Res, Oslo, Norway
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1717
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1403P
引用
收藏
页码：S889 / S889
页数：1
相关论文
共 50 条
  • [1] EGFR-mutation testing and TKI treatment patterns in locally advanced and metastatic NSCLC in Norway - A nationwide retrospective cohort study
    Helland, Aslaug
    Andersen, Klaus Kaae
    Myklebust, Tor age
    Johannesen, Tom Borge
    Aaroe, Jorgen
    Enerly, Espen
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2022, 33
  • [2] DISPARITIES IN ACCESS TO EGFR-MUTATION TESTING IN PATIENTS WITH ADVANCED NSCLC IN GERMANY 2011
    Kellermann, L.
    Ukena, D.
    VALUE IN HEALTH, 2012, 15 (07) : A360 - A361
  • [3] EGFR-mutation testing, treatment patterns and clinical outcomes in patients with stage IB-IIIA non-small cell lung cancer in Norway-a nationwide cohort study
    Helland, Aslaug
    Myklebust, Tor Age
    Conte, Simona
    Frederiksen, Line Elmerdahl
    Aaroe, Jorgen
    Enerly, Espen
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2024, 38
  • [4] A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses
    Koopman, Bart
    Garcia, Betzabel N. Cajiao
    Kuijpers, Chantal C. H. J.
    Damhuis, Ronald A. M.
    van der Wekken, Anthonie J.
    Groen, Harry J. M.
    Schuuring, Ed
    Willems, Stefan M.
    van Kempen, Leon C.
    CANCERS, 2021, 13 (14)
  • [5] PANORAMA - Real world molecular testing, treatment patterns, and clinical outcomes in patients with EGFR mutation-positive locally advanced or advanced NSCLC
    Griesinger, F.
    Buettner, R.
    Deppermann, K. -M.
    Reinmuth, N.
    Schuette, W.
    Thomas, M.
    Bergner, S.
    Schumann, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 248 - +
  • [6] IMPACT OF SAMPLE COLLECTION METHOD FOR EGFR MUTATION TESTING: RESULTS OF BLOOD-BASED AND TISSUE-BASED COBASA® EGFR MUTATION TESTING IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NSCLC IN THE US
    Poulios, N.
    Hristova-Neeley, D.
    Gavaghan, M.
    VALUE IN HEALTH, 2015, 18 (03) : A41 - A42
  • [7] Metastatic Site Location Influences the Diagnostic Accuracy of ctDNA EGFR-Mutation Testing in NSCLC Patients: a Pooled Analysis
    Passiglia, Francesco
    Rizzo, Sergio
    Rolfo, Christian
    Galvano, Antonio
    Bronte, Enrico
    Incorvaia, Lorena
    Listi, Angela
    Barraco, Nadia
    Castiglia, Marta
    Calo, Valentina
    Bazan, Viviana
    Russo, Antonio
    CURRENT CANCER DRUG TARGETS, 2018, 18 (07) : 697 - 705
  • [8] Metastatic site location may influence the diagnostic accuracy of plasma EGFR-mutation testing in NSCLC: A pooled analysis
    Passiglia, F.
    Listi, A.
    Barraco, N.
    Galvano, A.
    Fanale, D.
    Incorvaia, L.
    Bazan, V.
    Rolfo, C.
    Russo, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] Randomized Study of Pemetrexed Versus Erlotinib as Maintenance Therapy in Metastatic / Locally Advanced EGFR Mutation Negative NSCLC
    Joshi, A.
    Noronha, V.
    Patil, V.
    Sharma, M.
    Vora, C.
    Talreja, V.
    Goud, S.
    More, S.
    Shah, S.
    Mahajan, A.
    Janu, A.
    Kaushal, R.
    Prabhash, K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2088 - S2088
  • [10] Time to EGFR-TKI Treatment for Patients with Advanced NSCLC and EGFR Activating Mutation in a Tertiary Cancer Center
    Le Guevelou, Jennifer
    Dugue, Audrey
    Richard, Nicolas
    Dubos, Catherine
    Do, Pascal
    Danhier, Serge
    Lerouge, Delphine
    Bonneau, Jessica
    Blanc, Cecile
    Gervais, Radj
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1229 - S1229
12345